Journal Description
Cardiovascular Medicine
Cardiovascular Medicine
is an international, peer-reviewed, scholarly, open access journal that covers the entire spectrum of cardiovascular medicine, published quarterly online by MDPI (from Volume 28, Issue 1 - 2025). The Swiss Society of Perfusion (SSoP) and the Swiss Society of Cardiac Surgery (SGHC/SSCC) are affiliated with Cardiovascular Medicine and their members receive a discount on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, Embase, and other databases
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.4 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2026).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- Journal Cluster of Cardiology and Cardiovascular Medicine: Journal of Cardiovascular Development and Disease, Cardiogenetics, Hearts, Journal of Vascular Diseases, Cardiovascular Medicine, Kidney and Dialysis and Journal of CardioRenal Medicine.
Latest Articles
Heart Rate Variability in Heart Failure: Mechanisms, Prognostic Value and Modulation Strategies
Cardiovasc. Med. 2026, 29(3), 30; https://doi.org/10.3390/cardiovascmed29030030 - 5 Aug 2026
Abstract
►
Show Figures
Heart rate variability (HRV) is a non-invasive marker of cardiac autonomic regulation that reflects the dynamic interaction between sympathetic and parasympathetic influences on the sinoatrial node. Reduced HRV is a hallmark of autonomic dysfunction and has been consistently associated with adverse outcomes across
[...] Read more.
Heart rate variability (HRV) is a non-invasive marker of cardiac autonomic regulation that reflects the dynamic interaction between sympathetic and parasympathetic influences on the sinoatrial node. Reduced HRV is a hallmark of autonomic dysfunction and has been consistently associated with adverse outcomes across a wide range of cardiovascular conditions, particularly heart failure (HF). HRV is markedly reduced in HF, reflecting profound autonomic imbalance characterized by vagal withdrawal, impaired baroreflex sensitivity, and altered cardiorespiratory coupling. In heart failure with reduced ejection fraction (HFrEF), lower global HRV, particularly reduced SDNN, is consistently associated with mortality, sudden cardiac death, and disease progression. In heart failure with preserved ejection fraction (HFpEF), emerging observational evidence suggests that HRV alterations may accompany early autonomic dysregulation and may be associated with sex-specific patterns, although their mechanistic and prognostic significance remains incompletely defined. In acute HF, HRV assessed during hospitalization may provide additional prognostic information, although current evidence remains limited and heterogeneous. Pharmacological therapies, cardiac resynchronization therapy, exercise training, and lifestyle interventions have variably modulated HRV across studies, but the evidence is heterogeneous and changes in HRV should not be assumed to translate directly into improved clinical outcomes. Despite persistent challenges related to methodological standardization and clinical implementation, emerging technologies and multimodal approaches may refine the feasibility of integrating HRV into risk assessment frameworks. This narrative review aims to summarize the physiological basis of HRV, critically evaluate its alterations across different HF phenotypes, and discuss its prognostic associations, therapeutic modulation, and current practical limitations in clinical application.
Full article
Open AccessOpinion
Mechanism-Informed Drug Repurposing in MINOCA: Therapeutic Rationale and Trial Framework for Empagliflozin and Colchicine
by
Zainab Atiyah Dakhil
Cardiovasc. Med. 2026, 29(3), 29; https://doi.org/10.3390/cardiovascmed29030029 - 3 Aug 2026
Abstract
►▼
Show Figures
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a clinically important but heterogeneous syndrome associated with substantial long-term morbidity and adverse cardiovascular outcomes. Pharmacologic management remains largely extrapolated from obstructive coronary artery disease, creating a persistent mismatch between treatment strategies and the diversity
[...] Read more.
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a clinically important but heterogeneous syndrome associated with substantial long-term morbidity and adverse cardiovascular outcomes. Pharmacologic management remains largely extrapolated from obstructive coronary artery disease, creating a persistent mismatch between treatment strategies and the diversity of underlying mechanisms. Accurate diagnostic adjudication using cardiac magnetic resonance imaging, intracoronary imaging, coronary functional testing, and mechanistic biomarkers is therefore central to a phenotype-guided therapeutic approach. Inflammation, endothelial dysfunction, oxidative stress, autonomic dysregulation, coronary microvascular dysfunction, plaque-related injury, and adverse ventricular remodeling represent potentially targetable biological domains across selected MINOCA phenotypes. Empagliflozin and colchicine exert overlapping but distinct effects on several of these pathways and have demonstrated cardiovascular benefits in related clinical settings; however, direct evidence in MINOCA remains limited and predominantly observational. This article integrates the available mechanistic and clinical evidence into a comparative, phenotype-linked therapeutic framework and proposes a pragmatic trial strategy incorporating diagnostic adjudication, phenotype enrichment, biomarker-guided stratification, and adaptive or factorial designs. The proposed framework is hypothesis-generating and is intended to inform prospective investigation rather than support off-label prescribing or changes to current clinical practice.
Full article

Graphical abstract
Open AccessArticle
Ticagrelor or Clopidogrel After PCI in Atrial Fibrillation? Insights from a Real-World Retrospective Analysis
by
Ferhat Siyamend Yurdam and Ahmet Anıl Başkurt
Cardiovasc. Med. 2026, 29(3), 28; https://doi.org/10.3390/cardiovascmed29030028 - 3 Aug 2026
Abstract
►▼
Show Figures
Background: Optimal antithrombotic therapy in patients with AF undergoing PCI while receiving OAC remains a clinical challenge. Although clopidogrel is generally recommended as the preferred P2Y12 inhibitor in this setting, evidence comparing clopidogrel with ticagrelor in real-world AF–PCI populations is limited. Objective: To
[...] Read more.
Background: Optimal antithrombotic therapy in patients with AF undergoing PCI while receiving OAC remains a clinical challenge. Although clopidogrel is generally recommended as the preferred P2Y12 inhibitor in this setting, evidence comparing clopidogrel with ticagrelor in real-world AF–PCI populations is limited. Objective: To evaluate ischemic and bleeding outcomes in AF patients treated with DOAC combined with clopidogrel, ticagrelor, or TAT following PCI for ACS. Methods: This study involved 248 consecutive patients with non-valvular AF who underwent PCI for ACS and were discharged on DOAC plus clopidogrel (Group 1), DOAC plus ticagrelor (Group 2), or aspirin + clopidogrel + DOAC (Group 3). Cox regression analysis was used to determine the difference in survival rates among the three groups regarding the composite ischemic endpoint (stroke, MI, and stent restenosis) and bleeding. Results: In the Cox regression analysis performed, no statistically significant effect of the variables representing the antiplatelet treatment groups on ischemic outcomes was observed during the 1-year follow-up (Wald = 3.681; df = 2; p = 0.159). Conclusions: In this retrospective real-world cohort of AF patients undergoing PCI for ACS, clopidogrel-based dual therapy appeared to provide clinical outcomes comparable to ticagrelor with respect to thromboembolic and bleeding events. No clear ischemic advantage of ticagrelor was observed, although a numerical increase in minor bleeding was noted.
Full article

Graphical abstract
Open AccessArticle
The Biaxillary Access: A Cadaveric Proof-of-Concept Study of a Minimally Invasive Strategy for Combined Coronary Artery Bypass Grafting and Valve Surgery
by
Sahra Tasdelen, Thomas Poschner, Gianluca Dimonte, Sami Mouritane, Andrei-Antonio Caracioni, Viktoriia Tymoshenko and Martin Andreas
Cardiovasc. Med. 2026, 29(3), 27; https://doi.org/10.3390/cardiovascmed29030027 - 28 Jul 2026
Abstract
►▼
Show Figures
Coronary artery bypass grafting is frequently performed in combination with valve surgery; however, minimally invasive approaches for such combined procedures remain limited due to challenges in exposure and access. While bilateral minimally invasive strategies have been described in selected cases, standardized access concepts
[...] Read more.
Coronary artery bypass grafting is frequently performed in combination with valve surgery; however, minimally invasive approaches for such combined procedures remain limited due to challenges in exposure and access. While bilateral minimally invasive strategies have been described in selected cases, standardized access concepts for concomitant procedures are not well defined. This study aimed to assess the anatomical accessibility and procedural workflow of a minimally invasive biaxillary access strategy for combined coronary and valve surgery in a human cadaver model. Combined coronary artery bypass grafting and valve procedures were performed in nine Thiel/ethanol-fixed human cadavers using a biaxillary access approach. Anatomical exposure, conduit length, graft harvesting and anastomosis times, and valve positioning were evaluated by macroscopic inspection and postprocedural three-dimensional computed tomography imaging. All planned procedural steps were completed in all nine cadavers. The mean left and right internal thoracic artery lengths were 18.1 ± 1.8 cm and 18.9 ± 1.9 cm, respectively. The average bilateral internal thoracic artery harvest and anastomosis times were 52.0 ± 17.6 min and 46.6 ± 12.6 min, respectively. Postprocedural three-dimensional computed tomography imaging and macroscopic inspection demonstrated consistent graft positioning and anatomical valve seating across all specimens. This cadaveric study demonstrates that a minimally invasive biaxillary access strategy allows anatomical exposure and supports a conceptual procedural workflow for combined coronary and valve interventions. These findings represent an early-stage technical proof-of-concept and require further validation before clinical application can be considered.
Full article

Graphical abstract
Open AccessCase Report
Hybrid Approach for Distal Stent Graft-Induced New Entry After Frozen Elephant Trunk: Case Report
by
Boris N. Kozlov, Dmitri S. Panfilov, Evgeniya V. Lelik and Elizaveta A. Petrakova
Cardiovasc. Med. 2026, 29(3), 26; https://doi.org/10.3390/cardiovascmed29030026 - 15 Jul 2026
Abstract
►▼
Show Figures
This case demonstrates the efficacy and feasibility of visceral–renal debranching with endovascular repair for the treatment of a distal stent graft-induced new entry (dSINE) that occurred 47 months after a frozen elephant trunk procedure in a patient with chronic aortic dissection type B.
[...] Read more.
This case demonstrates the efficacy and feasibility of visceral–renal debranching with endovascular repair for the treatment of a distal stent graft-induced new entry (dSINE) that occurred 47 months after a frozen elephant trunk procedure in a patient with chronic aortic dissection type B. There were no perioperative complications. Postoperative computed tomography scans confirmed sealing dSINE and the patency of visceral and renal arteries.
Full article

Figure 1
Open AccessArticle
Risk Stratification of Postoperative Vasoplegia After Cardiac Surgery
by
Fabian Emrich, Lucia Lemaire, Afsaneh Karimian-Tabrizi, Marcus Hermann, Reza Fereidooni, Hanna Reichegger, Mustafa Al-Obaidi, Thomas Walther and Andreas Winter
Cardiovasc. Med. 2026, 29(3), 25; https://doi.org/10.3390/cardiovascmed29030025 - 15 Jul 2026
Abstract
►▼
Show Figures
Vasoplegic syndrome is a common and potentially life-threatening complication following cardiac surgery with cardiopulmonary bypass. It is characterized by profound hypotension due to persistently reduced systemic vascular resistance despite preserved or increased cardiac output. The reported incidence ranges from 8% to 44%, and
[...] Read more.
Vasoplegic syndrome is a common and potentially life-threatening complication following cardiac surgery with cardiopulmonary bypass. It is characterized by profound hypotension due to persistently reduced systemic vascular resistance despite preserved or increased cardiac output. The reported incidence ranges from 8% to 44%, and severe, catecholamine-resistant forms are associated with markedly increased mortality. In this retrospective study, 3937 cardiac surgical patients treated at the University Hospital Frankfurt between 2017 and 2021 were analyzed. Postoperative vasoplegic syndrome occurred in 17.5% of the cases and was classified as mild to moderate or severe according to vasopressor requirements. Preoperative, intraoperative, and postoperative variables were assessed using descriptive statistics as well as univariate and multivariable regression analyses to identify independent risk factors. Advanced age, elevated body mass index, EuroSCORE II > 10%, arterial degenerative diseases, preoperative dialysis dependence, atrioventricular valve surgery, emergency procedures, prolonged cardiopulmonary bypass and operative times, blood loss or transfusion and elevated preoperative hematocrit were identified as independent risk factors. Postoperatively, impaired renal function, increased inflammatory markers, and low hemoglobin levels were associated with vasoplegic syndrome. Severe vasoplegic syndrome was associated with increased mortality, prolonged intensive care unit stay, and extended hospitalization. Further research is required to establish standardized definitions and optimize prevention and treatment strategies.
Full article

Figure 1
Open AccessCase Report
A Clinical Experience with a Complex Case Treated with TriCValve®: Narrative Review of the Medical Literature and Rehabilitative Implications
by
Valerio Massimo Magro, Nicola Manocchio, Andrea Sorbino, Paola Russo, Anjeza Ago, Rita Mandarello, Gianluca Massaro, Concetta Ljoka, Gaetano Chiricolo and Calogero Foti
Cardiovasc. Med. 2026, 29(3), 24; https://doi.org/10.3390/cardiovascmed29030024 - 8 Jul 2026
Abstract
►▼
Show Figures
Tricuspid regurgitation (TR) is being increasingly recognized in the patient population. It is a common cardiac cause of chronic disability. This pathology is characterized by a heterogeneous and broad spectrum of clinical manifestations with signs and symptoms. The results from various and different
[...] Read more.
Tricuspid regurgitation (TR) is being increasingly recognized in the patient population. It is a common cardiac cause of chronic disability. This pathology is characterized by a heterogeneous and broad spectrum of clinical manifestations with signs and symptoms. The results from various and different analyses and studies suggest that TR-related deaths may have increased over the last 20 years. This trend may justify a greater focus on timely diagnosis and management of TR. For a long time, this problem has been underestimated or treated with only pharmacological therapy (diuretics). The use of the isolated surgical option remains infrequent, especially in patients at high surgical risk, for whom a significant number of patients with TR are still not treated, and a disability remains that is difficult to manage and rehabilitate. To date, there are emerging as an alternative to surgery in high-risk patients with severe TR multiple transcatheter devices that aim to reduce TR through different functional mechanisms. There are numerous minimally invasive treatments for TR, and many devices used for the treatment of this disabling pathology. In fact, there are various treatments with a transcatheter approach using ever-new devices. The use of heterotopic implantation of bioprosthetic valves in the superior and inferior vena cava represents an additional therapeutic armamentarium that, through caval reflux, can constitute an additional resource, too. Starting from a single clinical experience and describing a clinical case report, a narrative review has been undertaken by reviewing the various studies that have investigated this type of approach and their impact on the general, cardiac, and functional sides, to then discuss the cost–benefit ratio in light of knowledge on this specific topic.
Full article

Figure 1
Open AccessTechnical Note
Four-Dimensional Cinematic Rendering of a Presumed Aortic Valve Papillary Fibroelastoma on Coronary CT Angiography
by
Muhammad Umair and Amy Avakian
Cardiovasc. Med. 2026, 29(3), 23; https://doi.org/10.3390/cardiovascmed29030023 - 2 Jul 2026
Abstract
►▼
Show Figures
Four-dimensional cinematic rendering represents a convergence of physically based volumetric visualization and time-resolved cardiac imaging, enabling simultaneous assessment of structure and motion within a continuous spatial context. Its application to valvular pathology remains limited. We present a technical implementation of four-dimensional cinematic rendering
[...] Read more.
Four-dimensional cinematic rendering represents a convergence of physically based volumetric visualization and time-resolved cardiac imaging, enabling simultaneous assessment of structure and motion within a continuous spatial context. Its application to valvular pathology remains limited. We present a technical implementation of four-dimensional cinematic rendering applied to retrospectively electrocardiographically gated coronary computed tomography angiography for characterization of a presumed aortic valve papillary fibroelastoma. This approach enabled direct visualization of lesion morphology, stalk attachment, and dynamic mobility while preserving spatial relationships to valve cusps and the coronary ostium. In contrast to conventional two-dimensional and static three-dimensional techniques, four-dimensional cinematic rendering provided continuous spatial and temporal coherence, reducing interpretive fragmentation across imaging planes. Used as an adjunct to conventional cross-sectional interpretation, this method allows anatomical detail and functional behavior to be assessed concurrently, with potential implications for risk stratification and procedural planning in valvular disease.
Full article

Figure 1
Open AccessEditorial
Enhancing Invasive Coronary Angiography by Integrating Artificial Intelligence
by
Yuan Zhi, Florim Cuculi and Matthias Bossard
Cardiovasc. Med. 2026, 29(3), 22; https://doi.org/10.3390/cardiovascmed29030022 - 24 Jun 2026
Abstract
►▼
Show Figures
The recent rise of artificial intelligence (AI) has become unstoppable in cardiovascular medicine [...]
Full article

Figure 1
Open AccessReview
Cardiac CT in the Diagnosis and Management of Coronary Artery Fistulae
by
Mohamed Saber, Milos Prica, Reza Ashrafi, Damien Cullington, Ahmed Kharabish and Sarah Moharem-Elgamal
Cardiovasc. Med. 2026, 29(2), 21; https://doi.org/10.3390/cardiovascmed29020021 - 2 Jun 2026
Abstract
►▼
Show Figures
Coronary artery fistulae (CAF) are uncommon congenital or acquired coronary anomalies. A CAF occurs when a coronary artery bypasses the myocardial capillary bed to directly communicate with a cardiac chamber, a great vessel, or another vascular structure. Many CAFs are found by chance.
[...] Read more.
Coronary artery fistulae (CAF) are uncommon congenital or acquired coronary anomalies. A CAF occurs when a coronary artery bypasses the myocardial capillary bed to directly communicate with a cardiac chamber, a great vessel, or another vascular structure. Many CAFs are found by chance. If haemodynamically significant, a CAF may cause a variety of phenomena e.g., myocardial ischaemia, arrhythmias, heart failure, pulmonary hypertension, infective endocarditis/endarteritis, aneurysm formation, and late thrombotic complication. Management is anatomy-driven and dependent on the precise definition of the CAF’s origin, course, termination, multiplicity, associated coronary remodeling, and complications, together with an assessment of physiological relevance. Invasive coronary angiography is indispensable for real-time haemodynamics and transcatheter therapy, yet the two-dimensional projection nature can incompletely characterize complex CAF anatomy. Gated computed tomography coronary angiography (CTCA) produces high-resolution volumetric imaging with robust three-dimensional (3D) reconstruction and is central to contemporary diagnosis, quantitative risk stratification, procedural planning, and follow-up. This review examines the role of CTCA for the diagnosis and management of CAF and aims to provide a comprehensive overview for physicians managing this esoteric group of patients.
Full article

Figure 1
Open AccessEditorial
Continuing the Momentum of Cardiovascular Medicine—Highlights from the Second Issue
by
Peter Matt
Cardiovasc. Med. 2026, 29(2), 20; https://doi.org/10.3390/cardiovascmed29020020 - 28 May 2026
Abstract
We here present the second issue of Cardiovascular Medicine since its relaunch, with a breadth of contributions that is testament to the growing engagement of our community [...]
Full article
Open AccessReview
Hyponatremia in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Clinical Implications, and Management Challenges
by
Abbas Rachid, Ali G. Hmede, Mahmoud Kalash, Ali Tfaily and Ali El Sayed
Cardiovasc. Med. 2026, 29(2), 19; https://doi.org/10.3390/cardiovascmed29020019 - 20 May 2026
Abstract
►▼
Show Figures
Introduction: Hyponatremia is a common electrolyte abnormality in heart failure and has been consistently associated with worse clinical outcomes. While its prognostic value is well established in heart failure with reduced ejection fraction, its significance in heart failure with preserved ejection fraction remains
[...] Read more.
Introduction: Hyponatremia is a common electrolyte abnormality in heart failure and has been consistently associated with worse clinical outcomes. While its prognostic value is well established in heart failure with reduced ejection fraction, its significance in heart failure with preserved ejection fraction remains less clearly defined. Increasing evidence suggests that hyponatremia may reflect advanced neurohormonal activation, congestion, and cardiorenal dysfunction in this population. Methods: This study was conducted as a narrative review of the literature examining the pathophysiology, clinical implications, and management of hyponatremia in heart failure with preserved ejection fraction. Electronic databases including PubMed, EMBASE, Cochrane Library, Scopus, and Google Scholar were searched for relevant publications between 2010 and 2025. Eligible sources included clinical trials, observational studies, registry analyses, guideline documents, and review articles focusing on sodium disorders in heart failure populations. The findings were synthesized qualitatively to provide an integrated overview of the mechanisms, prognostic significance, and therapeutic considerations. Results: Available evidence indicates that hyponatremia occurs frequently in patients with heart failure with preserved ejection fraction and is associated with increased risks of mortality, rehospitalization, and cardiovascular events. The underlying mechanisms involve complex interactions between neurohormonal activation, impaired renal free water excretion, and therapeutic factors such as diuretic exposure. Hyponatremia appears to function primarily as a marker of disease severity rather than a direct mediator of adverse outcomes. Current management strategies primarily rely on general heart failure treatment principles, including optimizing diuretic therapy, managing fluid balance, and selectively using vasopressin antagonists. Conclusions: Hyponatremia represents an important biomarker of adverse prognosis in heart failure with preserved ejection fraction. Despite its clinical relevance, evidence guiding phenotype-specific management remains limited. Future research should focus on clarifying pathophysiologic mechanisms, improving risk stratification, and determining whether targeted correction of hyponatremia can improve clinical outcomes in this growing patient population.
Full article

Graphical abstract
Open AccessArticle
Cumulative LDL-C Burden and Incident Acute Coronary Syndrome in Type 2 Diabetes
by
Alan Saeed, Zhila Mohamed, Aisha Al Adab and Anas Kalfah
Cardiovasc. Med. 2026, 29(2), 18; https://doi.org/10.3390/cardiovascmed29020018 - 19 May 2026
Abstract
►▼
Show Figures
Background: Low-density lipoprotein cholesterol (LDL-C) is a central modifiable driver of atherosclerotic cardiovascular disease, yet cardiovascular risk in type 2 diabetes mellitus (T2DM) may be better captured by longitudinal LDL-C exposure than by a single LDL-C measurement. We examined the association of current
[...] Read more.
Background: Low-density lipoprotein cholesterol (LDL-C) is a central modifiable driver of atherosclerotic cardiovascular disease, yet cardiovascular risk in type 2 diabetes mellitus (T2DM) may be better captured by longitudinal LDL-C exposure than by a single LDL-C measurement. We examined the association of current LDL-C, cumulative LDL-C burden, and prior time below LDL-C targets with incident acute coronary syndrome (ACS) in patients with T2DM. Methods: We conducted a retrospective longitudinal cohort study using routinely collected electronic health-record data. Patients with T2DM and at least one valid LDL-C measurement between 1 January 2018 and 31 December 2023 were followed from the first eligible LDL-C measurement until incident ACS or administrative censoring on 31 March 2024. LDL-C was modeled using time-updated start–stop Cox regression. The primary exposure was current LDL-C category: <1.4, 1.4 to <1.8, 1.8 to <2.6, 2.6 to <3.4, 3.4 to <4.9, and ≥4.9 mmol/L. Secondary exposure metrics were cumulative LDL-C burden above prespecified thresholds and prior percentage of follow-up time below LDL-C targets. Models were adjusted for age, sex, hypertension, chronic kidney disease, HbA1c, T2DM duration, and calendar year of baseline LDL-C measurement; HbA1c and T2DM duration were multiply imputed. Results: The analytic cohort included 106,185 patients, 426,965 LDL-C intervals, and 5416 incident ACS events over 419,251.0 person-years. Compared with current LDL-C <1.4 mmol/L, adjusted ACS risk was higher for current LDL-C 3.4 to <4.9 mmol/L (HR 1.35, 95% CI 1.21–1.50) and ≥4.9 mmol/L (HR 1.94, 95% CI 1.63–2.32), whereas lower LDL-C categories were not clearly different from the reference category after adjustment. Each 1 mmol/L-year higher cumulative LDL-C burden was associated with higher ACS risk across evaluated thresholds, with HRs ranging from 1.04 to 1.13. Greater prior time below LDL-C targets was associated with lower ACS risk, with HRs of 0.97–0.98 per 10% higher time below target. Findings were consistent in sensitivity analyses restricted to patients with at least three LDL-C measurements, landmark analyses, and complete-case analysis. Conclusions: In patients with T2DM, incident ACS risk was associated with very high current LDL-C and with longitudinal LDL-C exposure captured by cumulative burden and time below target. These findings support sustained, target-oriented LDL-C control and suggest that longitudinal LDL-C metrics may complement single LDL-C values in cardiovascular risk assessment.
Full article

Figure 1
Open AccessCase Report
Fatal Suspected Kounis Syndrome Following Coronary Angiography in a Patient with Bladder Cancer
by
Haitham Ali Abdullah, Ali AbdulAmeer Al-Mousawi, Saif Abdul Azeez Qasim, Dhafer Yaseen Khudhair, Zaid Jawad Kadhim and Zainab Atiyah Dakhil
Cardiovasc. Med. 2026, 29(2), 17; https://doi.org/10.3390/cardiovascmed29020017 - 14 May 2026
Abstract
►▼
Show Figures
Background: Kounis syndrome is an acute coronary syndrome triggered by hypersensitivity reactions, which may result in coronary vasospasm, thrombosis, or stent-related complications. Case Summary: A 64-year-old male smoker with dyslipidemia and recently diagnosed urothelial carcinoma presented with exertional angina and underwent coronary angiography.
[...] Read more.
Background: Kounis syndrome is an acute coronary syndrome triggered by hypersensitivity reactions, which may result in coronary vasospasm, thrombosis, or stent-related complications. Case Summary: A 64-year-old male smoker with dyslipidemia and recently diagnosed urothelial carcinoma presented with exertional angina and underwent coronary angiography. Percutaneous coronary intervention was performed for a critical proximal–mid left anterior descending artery lesion using a drug-eluting stent. Immediately after stent deployment, the patient developed diffuse multivessel coronary vasospasm involving the left main stem, left anterior descending, and left circumflex arteries, accompanied by slow-flow/no-reflow phenomena and subsequent acute in-stent thrombosis. The clinical course rapidly progressed to ventricular arrhythmias and cardiogenic collapse. Despite transient return of spontaneous circulation after cardiopulmonary resuscitation, the patient developed fatal asystole during a repeat angiographic attempt. No cutaneous or respiratory allergic manifestations were observed. The abrupt onset of diffuse coronary dysfunction immediately following contrast exposure was suggestive of suspected Kounis syndrome, although mechanical causes and chemotherapy-related vasospasm could not be entirely excluded. Conclusions: Diffuse coronary vasospasm with multivessel dysfunction occurring abruptly after contrast exposure should raise suspicion for Kounis syndrome, even in the absence of overt allergic manifestations. Early recognition is essential to avoid misattribution to procedural complications and may be particularly important in patients with malignancy undergoing invasive coronary procedures.
Full article

Figure 1
Open AccessReview
Device-Related Thrombosis After Left Atrial Appendage Occlusion: Updated Management and Contemporary Challenges
by
Vincenzo Paragliola, Emanuele Chiarazzo, Andrea Giovanni Parato, Marcello Marchetta, Stefano Sasso, Giuseppe Massimo Sangiorgi, Andrea Natale and Mario Iannaccone
Cardiovasc. Med. 2026, 29(2), 16; https://doi.org/10.3390/cardiovascmed29020016 - 16 Apr 2026
Abstract
►▼
Show Figures
Percutaneous left atrial appendage occlusion (LAAO) has become an established alternative to long-term oral anticoagulation for stroke prevention in patients with atrial fibrillation, with expanding indications beyond those with absolute contraindications to anticoagulation. Alongside its broader adoption, device-related thrombus (DRT) has emerged as
[...] Read more.
Percutaneous left atrial appendage occlusion (LAAO) has become an established alternative to long-term oral anticoagulation for stroke prevention in patients with atrial fibrillation, with expanding indications beyond those with absolute contraindications to anticoagulation. Alongside its broader adoption, device-related thrombus (DRT) has emerged as a clinically relevant complication that directly compromises the protective intent of LAAO. This comprehensive narrative review synthesizes contemporary evidence on the incidence, mechanisms, predictors, clinical impact, and management of DRT. DRT is a multifactorial phenomenon that carries an annual incidence ranging from 1.75% to almost 5%, resulting from the interplay between post-implant flow dynamics, device engineering, endothelialization processes, procedural factors, and patient-specific prothrombotic features. Accumulating data from observational registries links DRT to increased risks of ischemic stroke, systemic embolism, major adverse cardiovascular events (MACE), and mortality. Although evidence is growing, optimal management regimens for both the prevention and treatment of DRT remain undefined. Moreover, a lack of standardization also affects diagnosis and imaging surveillance, mainly performed by transesophageal echocardiography or cardiac computed tomography. By integrating mechanistic insights, clinical predictors, device-specific considerations, and therapeutic evidence, this review highlights current knowledge gaps and proposes practical considerations to inform individualized risk stratification, surveillance, and management of DRT in contemporary LAAO practice.
Full article

Graphical abstract
Open AccessReview
Kv11.1 Channels in Cardiac Health and Disease: Molecular Insights and Clinical Relevance
by
Mitko Mladenov, Vadim Mitrokhin, Stanislav Schileyko, Anastasija Rodina, Alexandra Zolotareva, Valentin Zolotarev, Natalia Bocharnikova, Dmitry Kaminer, Emilija Antova, Radoslav Stojchevski, Slavica Josifovska, Dimiter Avtanski, Andre Kamkin and Nikola Hadzi-Petrushev
Cardiovasc. Med. 2026, 29(2), 15; https://doi.org/10.3390/cardiovascmed29020015 - 7 Apr 2026
Abstract
►▼
Show Figures
Kv11.1 (hERG1) channels, encoded by KCNH2, mediate the rapid delayed rectifier potassium current (IKr) crucial for cardiac repolarization. Disruptions, via mutations or antiarrhythmic drugs like dofetilide cause severe arrhythmogenic disorders, including Long QT Syndrome Type 2 (LQT2), Brugada Syndrome
[...] Read more.
Kv11.1 (hERG1) channels, encoded by KCNH2, mediate the rapid delayed rectifier potassium current (IKr) crucial for cardiac repolarization. Disruptions, via mutations or antiarrhythmic drugs like dofetilide cause severe arrhythmogenic disorders, including Long QT Syndrome Type 2 (LQT2), Brugada Syndrome (BrS), and Torsades de Pointes (TdP). While Kv11.1’s role in channelopathies and drug-induced arrhythmias is established, understanding its complex regulation and therapeutic targeting remains a challenge. This review synthesizes the structural, functional, and regulatory aspects of Kv11.1 channels and their clinical implications. Recent studies using iPSC-derived cardiomyocytes highlight regulation by PI3K/Akt, PKC, and PKA signaling via phosphorylation (Ser283, Ser890) and interactions with proteins like 14-3-3. Beyond electrophysiology, Kv11.1 influences pathological hypertrophy and non-cardiac functions including insulin secretion. Pharmacological efforts focus on activators to shorten action potential duration and suppress TdP, and blockers with overdose risks. Mutation heterogeneity, exemplified by trafficking impairment (G785D) in LQT2 and gain-of-function (R397C) in BrS, complicates precision therapy. Clinically, systematic risk stratification using electrocardiographic parameters and genotype-specific approaches enables personalized management. Beta-blockers remain first-line therapy for LQTS2, while rigorous avoidance of QT-prolonging medications and electrolyte monitoring form the cornerstones of preventive care. Advancing Kv11.1-targeted therapies with approaches like CRISPR-Cas9 and pharmacological chaperones (e.g., lumacaftor) holds promise for personalized treatments, ultimately reducing arrhythmic events and sudden cardiac death.
Full article

Figure 1
Open AccessReview
Excimer Laser Atherectomy: Mechanisms and Applications in Coronary and Peripheral Arteries
by
Ferrazzo Giuseppe, Giulia Laterra, Giampiero Avruscio, Carmen Tirrito, Sonia Ragazzo, Orazio Strazzieri, Lorenzo Scalia, Giampiero Vizzari, Antonio Micari, Paolo Mazzone, Giovanni Ruscica, Giorgio Sacchetta, Marco Contarini and Marco Barbanti
Cardiovasc. Med. 2026, 29(2), 14; https://doi.org/10.3390/cardiovascmed29020014 - 1 Apr 2026
Cited by 1
Abstract
►▼
Show Figures
The use of excimer laser atherectomy (ELA) has significantly evolved from the mid-1990s to the present, showing substantial improvements in both coronary and peripheral artery interventions. Initially associated with suboptimal outcomes due to low-energy settings and limited techniques, advancements such as high-energy delivery,
[...] Read more.
The use of excimer laser atherectomy (ELA) has significantly evolved from the mid-1990s to the present, showing substantial improvements in both coronary and peripheral artery interventions. Initially associated with suboptimal outcomes due to low-energy settings and limited techniques, advancements such as high-energy delivery, improved catheter designs, contrast injection protocols, and refined procedural approaches have greatly enhanced clinical efficacy. In coronary applications, ELA has become an established technique for treating intracoronary thrombus, under-expanded stents, in-stent restenosis, and heavily calcified lesions, offering favorable procedural and clinical outcomes with low complication rates. The excimer laser operates through photochemical, photothermal, and photomechanical mechanisms, enabling precise plaque ablation with minimal collateral damage. In peripheral interventions, especially in critical limb ischemia (CLI), ELA has emerged as a viable option for complex, non-crossable lesions and in-stent restenosis, demonstrating high technical success, improved patency, and promising limb salvage rates. Multiple clinical trials and registries support the safety and effectiveness of ELA, particularly in high-risk patient populations. This narrative review summarizes current evidence and practical considerations on the use of excimer laser atherectomy in coronary and peripheral interventions.
Full article

Figure 1
Open AccessArticle
Anatomy-Specific Association of Circulating Sortilin with Proximal Left Anterior Descending Artery Obstruction
by
Alim Namitokov, Irina Gilevich, Olga Malyarevskaya, Natalia Iraklionova, Karina Karabakhtsieva and Dana Namitokova
Cardiovasc. Med. 2026, 29(2), 13; https://doi.org/10.3390/cardiovascmed29020013 - 25 Mar 2026
Abstract
►▼
Show Figures
Background: Sortilin (SORT1), linked to the 1p13.3 coronary risk locus, is implicated in lipid trafficking and atherogenesis; however, clinical studies of circulating SORT1 have produced inconsistent results. We evaluated whether circulating SORT1 is associated with angiographic burden and lesion localization in patients with
[...] Read more.
Background: Sortilin (SORT1), linked to the 1p13.3 coronary risk locus, is implicated in lipid trafficking and atherogenesis; however, clinical studies of circulating SORT1 have produced inconsistent results. We evaluated whether circulating SORT1 is associated with angiographic burden and lesion localization in patients with premature or early clinical debut coronary atherosclerosis. Methods: This single-center, cross-sectional study analyzed a dataset collected from January to May 2023. Participants were classified as coronary atherosclerosis cases if the dataset contained an age of clinical debut of clinically significant atherosclerosis (n = 101). Controls had no recorded debut age and 0% stenosis in all assessed coronary segments (n = 27). Blood was collected in clot activator tubes; serum was stored at −40 °C until analysis. SORT1 (ng/mL) was measured using an Aviscera Bioscience ELISA. Coronary stenoses were recorded as percent diameter stenosis for left main (LM), proximal/mid/distal LAD, proximal/mid/distal LCx, and proximal/mid/distal RCA. Burden metrics included the number of segments with any stenosis (>0%), the number of obstructive segments (≥50%), the number of diseased vessels, and maximum stenosis. The prespecified primary endpoint was obstructive proximal LAD stenosis (≥50%). Nonparametric tests and Spearman correlations were used. Logistic regression evaluated the association between log2-transformed SORT1 and proximal LAD obstruction, adjusted for age, sex, LDL-C, statin use, and smoking/diabetes/hypertension durations. Results: SORT1 was higher in cases than controls (8.60 [2.60–17.10] vs. 2.30 [1.25–10.65] ng/mL; p = 0.0058). Within cases, SORT1 did not correlate with global angiographic burden (any-stenosis segments: ρ = −0.066, p = 0.513; obstructive segments: ρ = −0.060, p = 0.552; diseased vessels: ρ = −0.045, p = 0.652; maximum stenosis: ρ = −0.084, p = 0.403). Obstructive proximal LAD stenosis occurred in 44/101 (43.6%) and was associated with higher SORT1 (12.25 [4.18–17.45] vs. 4.10 [2.20–11.60] ng/mL; p = 0.0093). Each doubling of SORT1 was independently associated with proximal LAD obstruction (adjusted OR 1.48, 95% CI 1.12–1.95; p = 0.005). Conclusions: In this cross-sectional cohort, circulating SORT1 was associated with obstructive proximal LAD stenosis but not with global angiographic burden metrics. These findings are hypothesis-generating and warrant validation in independent cohorts with standardized preanalytics and prospective designs to assess temporal relationships and clinical utility.
Full article

Graphical abstract
Open AccessArticle
Atrial Fibrillation as a Marker of High-Risk Phenotype in Acute Coronary Syndrome
by
Gamze Yeter Arslan and Erkan Baysal
Cardiovasc. Med. 2026, 29(1), 12; https://doi.org/10.3390/cardiovascmed29010012 - 9 Mar 2026
Cited by 1
Abstract
►▼
Show Figures
Background: Atrial fibrillation (AF) is frequently encountered in patients presenting with acute coronary syndrome (ACS); however, its clinical significance beyond being a simple rhythm disturbance remains debated. We hypothesized that AF at presentation may be associated with a high-risk clinical profile characterized
[...] Read more.
Background: Atrial fibrillation (AF) is frequently encountered in patients presenting with acute coronary syndrome (ACS); however, its clinical significance beyond being a simple rhythm disturbance remains debated. We hypothesized that AF at presentation may be associated with a high-risk clinical profile characterized by hemodynamic instability and increased inflammatory and ischemic activity. Methods: This single-center, retrospective observational study included consecutive adult patients with acute coronary syndrome admitted to a tertiary cardiology center between January 2022 and December 2024. Patients were classified into two groups according to cardiac rhythm at presentation: AF and sinus rhythm. Baseline demographic characteristics, hemodynamic parameters, laboratory biomarkers, validated risk scores, and revascularization strategies were compared between groups. Multivariable logistic regression analysis was performed to evaluate whether AF was independently associated with a high-risk presentation, primarily defined by elevated GRACE risk score, reduced left ventricular ejection fraction, and increased inflammatory markers. Results: A total of 158 patients were included, of whom 50 (31.6%) presented with atrial fibrillation (mean age 71.2 ± 11.4 years, 46% female). Compared with patients in sinus rhythm, those with AF had significantly higher GRACE risk scores, lower left ventricular ejection fraction, faster heart rate, and higher white blood cell counts and peak high-sensitivity troponin levels. These associations remained significant after multivariable adjustment. Patients with AF also showed a numerically higher prevalence of severe angina at presentation. Conclusions: In patients presenting with ACS, atrial fibrillation is associated with a high-risk hemodynamic profile accompanied by increased inflammatory and ischemic activity. Rather than being an incidental finding, AF may represent a clinically relevant marker of acute cardiovascular stress and may contribute to early risk stratification in this setting.
Full article

Graphical abstract
Open AccessCase Report
OCT Findings from a Spontaneously Recanalized Coronary Thrombus Treated with a Drug-Coated Balloon
by
Firat Erdogan, Luca Vercelli, Mehdi Madanchi, Nicola von Rotz, Florim Cuculi and Matthias Bossard
Cardiovasc. Med. 2026, 29(1), 11; https://doi.org/10.3390/cardiovascmed29010011 - 2 Mar 2026
Cited by 1
Abstract
►▼
Show Figures
Background: Spontaneous recanalized coronary thrombus (SRCT) is an uncommon and often underrecognized coronary pathology that may be angiographically subtle despite having functional significance. Optical coherence tomography (OCT) enables accurate diagnosis and treatment planning. However, optimal treatment strategies remain incompletely defined. Materials and Methods:
[...] Read more.
Background: Spontaneous recanalized coronary thrombus (SRCT) is an uncommon and often underrecognized coronary pathology that may be angiographically subtle despite having functional significance. Optical coherence tomography (OCT) enables accurate diagnosis and treatment planning. However, optimal treatment strategies remain incompletely defined. Materials and Methods: A 55-year-old man presenting with severe exertional dyspnea, atypical chest pain episodes, and abnormal stress echocardiography underwent invasive coronary assessment with angiography, fractional flow reserve (FFR), and OCT. An SRCT of the left anterior descending artery (LAD) was identified and treated using OCT-guided lesion preparation followed by sirolimus-coated drug-coated-balloon (DCB) angioplasty. Results: Although there was only moderate angiographic disease, a functional assessment confirmed significant ischemia. OCT revealed a characteristic honeycomb morphology. Post-procedural OCT demonstrated satisfactory lumen gain, with preserved vessel integrity. Follow-up imaging showed vessel-healing and late lumen enlargement, and the patient remained asymptomatic. Conclusion: OCT-guided drug-coated-balloon angioplasty may be an effective “leave-nothing-behind” strategy for selected SRCT lesions, highlighting the importance of intracoronary imaging beyond angiography.
Full article

Figure 1
Journal Menu
► ▼ Journal MenuJournal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
- Vol. 27 (2024)
- Vol. 26 (2023)
- Vol. 25 (2022)
- Vol. 24 (2021)
- Vol. 23 (2020)
- Vol. 22 (2019)
- Vol. 21 (2018)
- Vol. 20 (2017)
- Vol. 19 (2016)
- Vol. 18 (2015)
- Vol. 17 (2014)
- Vol. 16 (2013)
- Vol. 15 (2012)
- Vol. 14 (2011)
- Vol. 13 (2010)
- Vol. 12 (2009)
- Vol. 11 (2008)
- Vol. 10 (2007)
- Vol. 9 (2006)
- Vol. 8 (2005)
- Vol. 7 (2004)
- Vol. 4 (2001)
- Vol. 3 (2000)
- Vol. 2 (1999)
- Vol. 1 (1998)
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Conferences
Special Issues
Special Issue in
Cardiovascular Medicine
Minimally Invasive Cardiac Surgery: How I Do It
Guest Editors: Peter Matt, Luca KoechlinDeadline: 31 December 2026




